Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00246935
Status:
COMPLETED
Last Update Posted:
2016-10-26
First Post:
2005-10-31
Brief Title:
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease APTA-2217-08
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Long-term Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this long-term study is to investigate the effect of roflumilast APTA-2217 on the long-term safety in patients with chronic obstructive pulmonary disease COPD who completed the 24-week evaluation of study APTA-2217-06 Roflumilast will be administered orally once daily The present study consists of a 28 weeks treatment period and is an extension of the 24-week study APTA-2217-06 registered study The study will provide further long-term safety and efficacy data of roflumilast
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None